March 13, 2020 / 9:43 PM / a month ago

BRIEF-Vanda Says FDA Refused Filing Of sNDA For Hetlioz For Treatment Of Smith-Magenis Syndrome

March 13 (Reuters) - Vanda Pharmaceuticals Inc:

* VANDA - RECEIVED LETTER FROM FDA IN WHICH FDA NOTIFIED CO OF ITS REFUSAL TO FILE CO’S SNDA FOR HETLIOZ FOR TREATMENT OF SMITH-MAGENIS SYNDROME

* VANDA PHARMACEUTICALS INC - IN LETTER, FDA ASSERTED THAT SNDA WAS NOT SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW BY FDA Source text: (bit.ly/2w3q4Eo) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below